HTR3A and cancer: Despite this, Kaiser et al.[26], Sugai at al.[15], and Goeke et al.[16] found that HTR3A polymorphisms were not good predictors of antiemetic treatment in cancer patients, SSRI-induced nausea, or NVP, respectively.